Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2000 participants
OBSERVATIONAL
2016-08-31
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Registration Program of BRCA1/2 Gene
NCT02593435
Research on the Heterogeneity of Taiwanese Breast Cancer Patients by Next Generation Sequencing (NGS) Tools
NCT04626440
Different Genetic Features Associated With Hepatic Carcinogenesis
NCT01247506
Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer
NCT02470819
Cell-free DNA Methylation Markers for Cancer Screening
NCT03096938
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two of the most prevalent breast cancer susceptibility genes are BRCA1and BRCA2. However，because of population based Genetic heterogeneity, the frequency of BRCA1/BRCA2 mutation is not as high in Caucasian population as in China. Anyway, the mean age at diagnosis of breast cancer in China is almost 10 years younger and more cases are diagnosed before 40 than those in Caucasians. Therefore, it is believed that there are certain specific susceptibility loci in Chinese breast cancers.
In preliminary experiments, investigators found two germline mutations may associate with Chinese breast cancers.
The purpose of the study is to determine the frequency of two germline mutations by sanger-sequencing in a larger sample of Chinese breast cancers
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chinese Breast Cancers
Woman with breast cancer that have been diagnosed in clinic
rs183489969,rs185670819
compare the frequency of two germline mutations in breast cancers and controls
healthy controls
Woman without breast cancer
rs183489969,rs185670819
compare the frequency of two germline mutations in breast cancers and controls
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rs183489969,rs185670819
compare the frequency of two germline mutations in breast cancers and controls
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Song Hongping
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Song Hongping
PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
hongping song, PhD
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Fourth Military Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Fourth Military Medical University
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRCA-Genetics-2016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.